Corcept Therapeutics (CORT) Earnings Date, Estimates & Call Transcripts $53.63 +1.46 (+2.80%) (As of 05:36 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Corcept Therapeutics Latest Earnings SummaryActual EPS (Oct. 30) $0.41 Beat By $0.14 Consensus EPS (Oct. 30) $0.27 Corcept Therapeutics announced Q3 2024 earnings on October 30, 2024, reporting an EPS of $0.41, which beat analysts' consensus estimates of $0.27 by $0.14. Quarterly revenue rose 47.7% year-over-year to $182.55 million, above the consensus estimate of $171.97 million. With a trailing EPS of $1.26 and a P/E Ratio of 42.56, Corcept Therapeutics' earnings are expected to grow 36.30% next year, from $1.35 to $1.84 per share. Conference CallConference Call TranscriptPowered by Get Corcept Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corcept Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCORT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CORT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Corcept Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20244-$0.02$0.31$0.15 Q2 20244$0.20$0.36$0.25 Q3 20244$0.20$0.38$0.28 Q4 20244$0.26$0.46$0.36 FY 202416$0.64$1.51$1.04 Q1 20252$0.27$0.35$0.31 Q2 20252$0.34$0.41$0.38 Q3 20252$0.42$0.46$0.44 Q4 20252$0.47$0.53$0.50 FY 20258$1.50$1.75$1.63 Q1 20261$0.45$0.45$0.45 Q2 20261$0.55$0.55$0.55 Q3 20261$0.71$0.71$0.71 Corcept Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails10/30/2024Q3 2024$0.27$0.41+$0.14$0.41$171.97M$182.55M7/29/2024Q2 2024$0.23$0.32+$0.09$0.32$155.14M$163.80M5/1/2024Q1 2024$0.21$0.25+$0.04$0.25$141.19M$146.80M2/15/2024Q4 2023$0.25$0.28+$0.03$0.28$129.27M$135.41M11/1/2023Q3 2023$0.22$0.28+$0.06$0.28$119.71M$123.60M8/2/2023Q2 2023$0.15$0.25+$0.10$0.25$109.60M$117.72M Get the Latest News and Ratings for CORT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/3/2023Q1 2023$0.20$0.14 -$0.06$0.14$104.91M$105.70M2/28/2023Q4 2022$0.23$0.14 -$0.09$0.14$106.93M$103.06M Corcept Therapeutics Earnings - Frequently Asked Questions When did Corcept Therapeutics announce their last quarterly earnings? Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earning data on Wednesday, October 30, 2024. Learn more on CORT's earnings history. What guidance has Corcept Therapeutics issued on next quarter's earnings? Corcept Therapeutics updated its FY 2024 earnings guidance on Wednesday, October, 30th. The company issued revenue guidance of $675.0 million-$700.0 million, compared to the consensus revenue estimate of $661.1 million. Did Corcept Therapeutics beat their earnings estimates last quarter? In the previous quarter, Corcept Therapeutics (NASDAQ:CORT) reported $0.41 earnings per share (EPS) to beat the analysts' consensus estimate of $0.27 by $0.14. Learn more on analysts' earnings estimate vs. CORT's actual earnings. How can I listen to Corcept Therapeutics's earnings conference call? The conference call for Corcept Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Corcept Therapeutics's conference call transcript? The conference call transcript for Corcept Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Corcept Therapeutics generate each year? Corcept Therapeutics (NASDAQ:CORT) has a recorded annual revenue of $628.56 million. How much profit does Corcept Therapeutics generate each year? Corcept Therapeutics (NASDAQ:CORT) has a recorded net income of $106.14 million. CORT has generated $1.26 earnings per share over the last four quarters. What is Corcept Therapeutics's price-to-earnings ratio? Corcept Therapeutics (NASDAQ:CORT) has a trailing price-to-earnings ratio of 42.56 and a forward price-to-earnings ratio of 39.73. What is Corcept Therapeutics's EPS forecast for next year? Corcept Therapeutics's earnings are expected to grow from $1.35 per share to $1.84 per share in the next year, which is a 36.30% increase. More Earnings Resources from MarketBeat Related Companies Royalty Pharma Earnings Results Jazz Pharmaceuticals Earnings Results Perrigo Earnings Results Supernus Pharmaceuticals Earnings Results Pacira BioSciences Earnings Results Omeros Earnings Results Nektar Therapeutics Earnings Results Assembly Biosciences Earnings Results Cumberland Pharmaceuticals Earnings Results Eli Lilly and Company Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings Report [PDF] The Opportunity in Gold (Ad)Commodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.Tap here to read it This page (NASDAQ:CORT) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | Sponsored“AI Killer” 10x More Powerful Than ChatGPTElon Musk may be about to “kill” the world’s most powerful AI. Very few people are talking about the one AI...Paradigm Press | SponsoredIs Jeff Bezos Crowning the Next Nvidia?It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company ...InvestorPlace | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
